Surface-modified functionalized polycaprolactone scaffolds for bone repair: In vitro and in vivo experiments

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 9, 2014, Pages 2993-3003

  Jensen, Jonas ^a   Rölfing, Jan Hendrik Duedal ^a   Svend Le, Dang Quang ^a   Kristiansen, Asger Albæk ^b   Nygaard, Jens Vinge ^b   Hokland, Lea Bjerre ^a   Bendtsen, Michael ^a   Kassem, Moustapha ^c   Lysdahl, Helle ^a   Bünger, Cody Eric ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biodegradation; bone tissue engineering; foreign body giant cell; poly caprolactone; scaffold

Indexed keywords

BIODEGRADATION; BIOMATERIALS; BONE; COMPUTERIZED TOMOGRAPHY; PHASE SEPARATION; POLYCAPROLACTONE; SCAFFOLDS;

BONE MORPHOGENETIC PROTEIN-2; BONE TISSUE ENGINEERING; CAPROLACTONE; FOREIGN BODY GIANT CELLS; FUSED DEPOSITION MODELING; MICROCOMPUTED TOMOGRAPHY; NANOPOROUS STRUCTURES; POLYCAPROLACTONE SCAFFOLDS;

SCAFFOLDS (BIOLOGY);

BIOSCAFFOLDER; BONE MORPHOGENETIC PROTEIN 2; DIOXANE; FUSED DEPOSITION MODEL POLYCAPROLACTONE; NANOSTRUCTURED POROUS POLYCAPROLACTONE; POLYCAPROLACTONE; TISSUE SCAFFOLD; UNCLASSIFIED DRUG; POLYESTER;

ANIMAL EXPERIMENT; ARTICLE; AUTOGRAFT; BONE MASS; BONE REGENERATION; BONE REMODELING; BONE STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FREEZE DRYING; GIANT CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LANDRACE PIG; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MONONUCLEAR CELL; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHASE SEPARATION; POROSITY; SCANNING ELECTRON MICROSCOPY; STUDY DESIGN; TISSUE SECTION; ANIMAL; BONE DEVELOPMENT; CELL LINE; CHEMISTRY; DRUG EFFECTS; INJURIES; PHYSIOLOGY; PROCEDURES; SKULL; SURFACE PROPERTY; SWINE; TISSUE ENGINEERING; TISSUE SCAFFOLD; ULTRASTRUCTURE;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELL LINE; FEMALE; HUMANS; OSTEOGENESIS; POLYESTERS; SKULL; SURFACE PROPERTIES; SWINE; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84904822517     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34970     Document Type: Article

References (38)

1. Williams D,. Benefit and risk in tissue engineering. Mater Today 2004; 7: 24-29.
2. Drotleff S, Lungwitz U, Breunig M, Dennis A, Blunk T, Tessmar J, Göpferich A,. Biomimetic polymers in pharmaceutical and biomedical sciences. Eur J Pharm Biopharm 2004; 58: 385-407.
3. Shin H, Jo S, Mikos AG,. Biomimetic materials for tissue engineering. Biomaterials 2003; 24: 4353-4364.
4. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR,. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials 2006; 27: 3413-3431.
5. Chuenjitkuntaworn B, Inrung W, Damrongsri D, Mekaapiruk K, Supaphol P, Pavasant P,. Polycaprolactone/hydroxyapatite composite scaffolds: Preparation, characterization, and in vitro and in vivo biological responses of human primary bone cells. J Biomed Mater Res A 2010; 94: 241-251.
6. Lee H, Kim G,. Three-dimensional plotted PCL/β-TCP scaffolds coated with a collagen layer: Preparation, physical properties and in vitro evaluation for bone tissue regeneration. J Mater Chem 2011; 21: 6305.
7. Lohfeld S, Cahill S, Barron V, McHugh P, Dürselen L, Kreja L, Bausewein C, Ignatius A,. Fabrication, mechanical and in vivo performance of polycaprolactone/tricalcium phosphate composite scaffolds. Acta Biomater 2012; 8: 3446-3456.
8. Derby B,. Printing and prototyping of tissues and scaffolds. Science 2012; 338: 921-6.
9. Biondi M, Ungaro F, Quaglia F, Netti PA,. Controlled drug delivery in tissue engineering. Adv Drug Deliv Rev 2008; 60: 229-242.
10. Schantz J-T, Lim TC, Ning C, Teoh SH, Tan KC, Wang SC, Hutmacher DW,. Cranioplasty after trephination using a novel biodegradable Burr hole cover: Technical case report. Neurosurgery 2006; 58: ONS-E176; discussion ONS-E176.
11. Nygaard JV, Hokland LB, Bünger CE,. Three-dimensional nanostructured hybrid scaffold and manufacture thereof. Patent UA20120128739; 2010.
12. Christensen BB, Foldager CB, Hansen OM, Kristiansen AA, Le DQS, Nielsen AD, Nygaard JV, Bünger CE, Lind M,. A novel nano-structured porous polycaprolactone scaffold improves hyaline cartilage repair in a rabbit model compared to a collagen type I/III scaffold: In vitro and in vivo studies. Knee Surg Sports Traumatol Arthrosc 2012; 20: 1192-1204.
13. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SIS, Jensen TG, Kassem M,. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002; 20: 592-596.
14. Goldner J,. A modification of the masson trichrome technique for routine laboratory purposes. Am J Pathol 1938; 14: 237.
15. Abdallah BM, Ditzel N, Kassem M,. Assessment of bone formation capacity using in vivo transplantation assays: Procedure and tissue analysis. Methods Mol Biol 2008; 455: 89-100.
16. Oh SH, Park IK, Kim JM, Lee JH,. In vitro and in vivo characteristics of PCL scaffolds with pore size gradient fabricated by a centrifugation method. Biomaterials 2007; 28: 1664-1671.
17. Hulbert SF, Young FA, Mathews RS, Klawitter JJ, Talbert CD, Stelling FH,. Potential of ceramic materials as permanently implantable skeletal prostheses. J Biomed Mater Res 1970; 4: 433-456.
18. Kuboki Y, Jin Q, Takita H,. Geometry of carriers controlling phenotypic expression in BMP-induced osteogenesis and chondrogenesis. J Bone Joint Surg Am Vol 2001; 83-A suppl 1: S105-S115.
19. Kuboki Y, Jin Q, Kikuchi M, Mamood J, Takita H,. Geometry of artificial ECM: Sizes of pores controlling phenotype expression in BMP-induced osteogenesis and chondrogenesis. Connect Tissue Res 2002; 43: 529-534.
20. Karageorgiou V, Kaplan D,. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 2005; 26: 5474-5491.
21. Mygind T, Stiehler M, Baatrup A, Li H, Zou X, Flyvbjerg A, Kassem M, Bünger CE,. Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials 2007; 28: 1036-1047.
22. Bjerre L, Bünger C, Baatrup A, Kassem M, Mygind T,. Flow perfusion culture of human mesenchymal stem cells on coralline hydroxyapatite scaffolds with various pore sizes. J Biomed Mater Res A 2011; 97A: 251-263.
23. Bessa PC, Casal M, Reis RL,. Bone morphogenetic proteins in tissue engineering: The road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008; 2: 81-96.
24. Bessa PC, Casal M, Reis RL,. Bone morphogenetic proteins in tissue engineering: The road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2008; 2: 1-13.
25. Schantz J-T, Teoh SH, Lim TC, Endres M, Lam CXF, Hutmacher DW,. Repair of calvarial defects with customized tissue-engineered bone grafts I. Evaluation of osteogenesis in a three-dimensional culture system. Tissue Eng 2003; 9 suppl 1: S113-S126.
26. Rosengren A, Bjursten LM,. Pore size in implanted polypropylene filters is critical for tissue organization. J Biomed Mater Res 2003; 67A: 918-926.
27. Nauta AJ, Fibbe WE,. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
28. Sun H, Jung Y, Shiozawa Y, Taichman RS, Krebsbach PH,. Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone. Tissue Eng Part A 2012; 18: 2095-2105.
29. Pitt CG, Gratzl MM, Kimmel GL, Surles J, Schindler A,. Aliphatic polyesters II. The degradation of poly(dl -lactide), poly (epsilon-caprolactone) , and their copolymers in vivo. Biomaterials 1981; 2: 215-220.
30. Burkersroda FV, Schedl L, Göpferich A,. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23: 4221-4231.
31. Göpferich A,. Mechanisms of polymer degradation and erosion. Biomaterials 1996; 17: 103-114.
32. Ali SAM, Zhong SP, Doherty PJ, Williams DF,. Mechanisms of polymer degradation in implantable devices. Biomaterials 1993; 14: 648-656.
33. Lam CXF, Hutmacher DW, Schantz J-T, Woodruff MA, Teoh SH,. Evaluation of polycaprolactone scaffold degradation for 6 months in vitro and in vivo. J Biomed Mater Res A 2009; 90: 906-919.
34. Woodward SC, Brewer PS, Moatamed F, Schindler A, Pitt CG,. The intracellular degradation of poly(ε-caprolactone). J Biomed Mater Res 1985; 19: 437-444.
35. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, Chihara K,. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995; 10: 1681-1690.
36. Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T,. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Bioph Res Commun 1999; 259: 97-102.
37. Jensen ED, Pham L, Billington CJ, Espe K, Carlson AE, Westendorf JJ, Petryk A, Gopalakrishnan R, Mansky K,. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010; 109: 672-682.
38. Schlegel KA, Lang FJ, Donath K, Kulow JT, Wiltfang J,. The monocortical critical size bone defect as an alternative experimental model in testing bone substitute materials. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 7-13.